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2012.07.0Abstract Purpose: The aim of this work is to study the validity of cyclin D1 expression, a cell
cycle regulatory protein, on (ﬁne needle aspiration cytology) FNAC samples in patients with breast
carcinoma using immunostaining technique.
Patient and methods: This is a study done on 70 patients with primary breast carcinoma, presented
to Cytology Unit, Pathology Department, National Cancer Institute, Cairo University. They under-
went preoperative FNAC and diagnosed as breast carcinoma. The cytologic and tissue section slides
were subjected to cyclin D1 immunocytochemical staining. Only the nuclear immunoreactivity for
cyclin D1 was considered speciﬁc. The rate of concordance, and discordance, and kappa value were
calculated. Relation between cytologic expression of cyclin D1 and different clinicopathologic
parameters was evaluated.
Results: Cyclin D1 immunocytochemical expression was observed in 53/70 cases (75.7%) in cyto-
logic smears. In histologic sections of the corresponding cases, cyclin D1was detected in 48/70 cases
(68.6%). The concordance rate of cyclin D1 expression in the FNA and histologic sections was
87.1% while the discordance rate was 12.9%. Kappa showed a value of 0.65. A statistically signif-
icant relation was found between cyclin D1 immunocytochemical expression and hormonal status
as well as nuclear grade.
Conclusion: Cyclin D1 immunocytochemical expression can be performed successfully on cytologic
samples with a high concordance rate and agreement with histologic results. This can help in deter-
mining tumor biology, and plan for patients’ treatment. The marker showed a signiﬁcant relation
with hormone receptor status and nuclear grade.
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Worldwide, breast cancer comprised 22.9% of all cancers in
women, it caused 13.7% of cancer deaths among women in
the year 2008 [1]. In Egypt, breast cancer came as number
one in ranking of malignant tumors constituting 17.5% of totaland hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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National Cancer Institute during the years 2003–2004 [2]. Wide
acceptance of breast conservation surgery has increased the use
of preoperative chemotherapy to downstage locally advanced
breast carcinoma. Tumor biology may be altered after chemo-
therapy because of clonal selection. Pretreatment assessment of
tumor biology may be useful in determining a treatment plan
for individual patients with breast carcinoma. If the biologic
characteristics of the tumor could be assessed more precisely,
it might be possible to provide a more reasonable targeted ther-
apy to breast carcinoma patients while minimizing adverse side
effects [3].
The discovery and characterization of cell cycle regulatory
proteins have advanced our understanding of the cell cycle.
Both positive and negative regulators have been the target
for important research to unravel the mechanisms relating cell
cycle to cancer [4]. An increasing number of genes have been
implicated in the evolution of breast cancer, and this list is ex-
pected to expand with the development of new genomic tools.
Studies to date have relied on correlations between gene muta-
tion, gene expression and breast cancer phenotype to identify
candidate genes. Cyclin D1 is the product of the CCND1 gene
and was ﬁrst implicated in tumorigenesis following localization
to chromosome 11q1, a region of the genome that is commonly
ampliﬁed in a range of human carcinomas including breast
cancer [5]. Cyclin D1 plays a pivotal role in the regulation of
progression from the G1 to the S phase of the cell cycle
through the formation of active enzyme complexes with
cyclin-dependent kinases Cdk4 and Cdk6 [6]. The cyclin D1
gene is turned on at the beginning of the G1 phase upon receipt
of a cell cycle activation signal. It participates in oncogenesis
through ampliﬁcation of chromosome 11q1 locus, on which
it resides. Overexpression of cyclin D1 arising by this mecha-
nism correlated with signiﬁcant proportion of breast cancer [7].
The cyclin D1 gene is ampliﬁed in approximately 20% of
human breast carcinomas, and is overexpressed in approxi-
mately 50% of breast tumor. Cyclin D1 is one of the most
commonly overexpressed oncogene in breast carcinoma [8].
A number of studies have been conducted to determine
whether cyclin D1 is a useful biologic marker in the treatment
of breast carcinoma patients. Studies on primary breast can-
cers indicate that overexpression is conﬁned to speciﬁc pheno-
types, implying different roles in different subtypes of the
disease. Lobular carcinoma appears to universally overexpress
cyclin D1 [9], while overexpression in ductal carcinoma is con-
ﬁned almost exclusively to estrogen receptor positive cases [10].
A potential functional link between estrogen receptor (ER)
positivity and cyclin D1 overexpression is supported by evi-
dence that cyclin D1 plays a major role in estrogen-induced
mitogenesis in breast cancer cells [11].
Fine needle aspiration cytology is a well established diag-
nostic tool for the evaluation of breast lump [12]. Although ﬁne
needle aspiration has been mainly used for diagnostic purpose,
development of molecular biologic techniques enables the accu-
rate preoperative evaluation for biological nature of the cancers
especially there is an increasing number of patients unﬁt for
surgery either due to age or other medical conditions [7]. The
majority of the previous studies have used tissue sections for
cyclin D1 assay, while very few reports have examined cyclin
D1 immunocytochemical expression using ﬁne-needle aspira-
tion (FNA) samples. In these reports, cyclin D1 expression
was detected in up to 65% of cases [13].Aim of the work
Our study was conducted to evaluate the validity of immuno-
cytochemical expression of cyclin D1 in FNA samples from
patients with primary breast carcinoma by comparing the
immunocytochemical results with immunohistochemical
expression of cyclinD1 in parafﬁn-embedded tumor sections
of the same excised lumps.
Patients and methods
FNA smears were obtained from 70 cases presented with clin-
ically suspicious breast masses at Cytology Unit, Pathology
Department, National Cancer Institute, Cairo University from
March to October 2011. The patients’ ﬁles were reviewed and
information about age, size of the mass, radiological ﬁndings,
and any other relevant data were recorded.
Breast swellings were aspirated using 22/23 gauge dispos-
able needles ﬁtted to 5 ml plastic syringes using the standard
procedures [14]. The aspirated contents of the needle are
expelled onto glass slides. Five slides smear were made for each
case, they were immediately ﬁxed in 95% ethyl alcohol for
about 30 min at room temperature. Four slides were stained
using modiﬁed Papanicolaou stains [15], while one slide was
left unstained. Diagnosis of cytological smears was done
according to standard criteria deﬁned by various authors
[16]. Smears with inadequate cellularity or bad quality due to
delayed or inadequate ﬁxation were considered unsatisfactory
and excluded from the study. FNA results were compared with
the ﬁnal histopathological diagnosis. Cases proved cytologi-
cally to be malignant and had ﬁnal histopathological malig-
nant diagnoses of the same excised lumps were selected for
the study.
The unstained cytological smears as well as the 5 lm tissue
section of the corresponding excised specimens containing
breast carcinoma were subjected to immunostaining for cyclin
D1 according to the avidin-biotin complex (ABC) immunoper-
oxidase method using the rabbit monoclonal antibodies from
the manufacturer Thermo Scientiﬁc, USA, Cyclin D1 mAb
(clone; EPR2241IHC), 1:100 in antibody diluents. The reac-
tion was detected using Diaminobenzidine (DAB) with hydro-
gen peroxide (H2O2), and the slides were counterstained with
hematoxylin, and examined for cyclin D1 expression. Only
the nuclear immunoreactivity for cyclin D1 was considered
speciﬁc. Slides were reported as positive if >5% of the neo-
plastic cells showed nuclear staining [13], both in FNA smears
and in tissue sections. Histologic sections of mantle cell lym-
phoma were used as a positive control, and a negative control
was used by substituting Phosphate Buffer Saline (PBS) for the
primary antibody.
Results of the immunocytochemistry were compared with
those obtained by immunohistochemistry. Percentage of mar-
ker expression in cytologic smears and tissue sections, concor-
dance, discordance, and agreement rate were calculated.
Relation between immunocytochemical results of cyclin D1
expression and tumor size, lymph node metastasis, histologic
nuclear grade, hormone receptor status, and cytologic nuclear
grade was tested. A p value of <0.05 was taken as signiﬁcant.
Kappa statistics was used to assess the level of agreement;
Kappa values ranging from 0.61 to 0.8 were assumed to indi-
cate a very good agreement.
Figure 1 FNA of invasive duct carcinoma case showing positive
nuclear immunostaining to cyclin D1 (·100).
Table 1 Cyclin D1expression in the cytologic smears and the
corresponding tissue sections.
Cyclin D1 cytology Pathology Total Kappa
Positive Negative
Positive
Negative
46
2
7
15
53
17
0.65
Total 48 22 70
Figure 2 Histologic section of the same lump exhibiting nuclear
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The age of patient included in the present study ranged from
40 to 70 years, with a mean age of 51 years with standard devi-
ation 8.192. The median was 54 years. All patients were
females.
Forty eight patients (68.6%) presented with mass in the
right breast, and 22 lumps (31.4%) were in the left breast.
The masses were <2 cm in 5 patients (7.1%), 2–5 cm in 54 pa-
tients (77.1%), and >5 cm in 11 patients (15.7%). Fifty seven
patients (81.4%) had positive ipsilateral axillary lymph nodes,
while 13 patients (18.6%) showed no lymph node enlargement,
57 cases (81.4%) were classiﬁed cytologically as grade 2 tu-
mors, while 13 cases (18.6%) were considered as grade 3. By
referring to pathology reports; ﬁfty nine patients (84.3%)
showed histologic nuclear grade 2, where 11 patients (15.7%)
were considered as grade 3, 50 patients (71.4%) showed posi-
tive ER expression, while 20 patients (28.6%) were ER nega-
tive, 46 patients (65.7%) were progesterone receptor (PR)
positive, and 24 patients (34.3%) were PR negative (Table 2).
In FNA samples, cyclin D1 immunocytochemical expres-
sion was observed in 53/70 cases (75.7%) (Figs. 1, 3 and 5).
In histologic sections of the corresponding cases, cyclin D1Table 2 Correlation between cyclin D1 immunocytochemical
expression and different clinico-pathologic parameters.
Clinico-pathological
parameters
No. Cyclin D1 expression P Value
Positive Negative
Size
<2 cm 5 3 (60%) 2 (40%) 0.12
2–5 cm 54 44 (81.5%) 10 (18.5%)
>5 cm 11 6 (54.5%) 5 (45.5%)
L N status
Positive 57 46 (80.7%) 11 (19.3%) 0.07
Negative 13 7 (53.8%) 6 (46.2%)
Histologic nuclear grade
Grade 2 59 49 (83.1%) 10(16.9%) 0.004
Grade 3 11 4(36.4%) 7(63.6%)
Cytologic nuclear grade
Grade 2 57 48 (84.2%) 9 (15.8%) 0.002
Grade 3 13 5 (38.5%) 8 (61.5%)
ER status
Positive 50 46 (92%) 4 (8%) <0.001
Negative 20 7 (35%) 13 (65%)
PR status
Positive 46 44 (95.6%) 2 (8.4%) <0.001
Negative 24 9 (37.5%) 15 (62.5%)
immunoreactivity to cyclin D1 (·200).
Figure 3 Positive nuclear staining for cyclin D1 in invasive duct
carcinoma by immunocytochemistry (·400).positivity was detected in 48/70 cases (68.6%) (Figs. 2, 6 and
4). Cyclin D1 was expressed in 46 cases in both FNA samples
and histologic sections. Cyclin D1 expression was not observed
in 15 cases either by FNA or histologic tissue sections (Table 1).
Thus, the concordance rate of cyclin D1 expression in the FNA
and histologic sections was 87.1% (61/70) and the discordance
Figure 4 Positive nuclear staining with anti cyclin D1 antibody
in the same excised lump by immunohistochemistry (·400).
Figure 6 Histologic section of the same lump showing nuclear
immunoreactivity to cyclin D1 (·400).
Figure 7 Histologic section of the same case showing + 2
nuclear immunoreactivity to ER (·200).
Figure 5 FNA of a case of invasive duct carcinoma showing
positive nuclear staining for cyclin D1 (·400).
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a good agreement between cytologic and histologic results.
The results of the cyclin D1 immunocytochemical expres-
sion in FNA samples were analyzed according to the clinical
and histological characteristics of the included breast carcino-
mas cases. There was a signiﬁcant difference in cyclin D1
expression according to different parameters, apart from
lymph node status and tumor size.
A statistically signiﬁcant relation was found between histo-
logic nuclear grade and cyclin D1 immunocytochemical
expression (p value = 0.004), where 49 out of 59 tumors with
nuclear grade 2 (83.1%) showed positive reaction to cyclin D1,
while in higher grade tumors only 4 out of 11 cases (36.4%)
were positive. A signiﬁcant relation was observed between cy-
clin D1 immunocytochemical expression and cytologic grading
(p value = 0.002), as 48 out of 57 cytologic grade 2 cases
(84.2%) were positive for cyclin D1 expression, while only 5
of 13 cases of grade 3 tumors (38.5%) were positive (Table
2). As the histologic and the cytologic grade are relative to
each other and both are relative to cancer differentiation, thus
the relation between cyclin D1 expression and histologic and
cytologic grade will be discussed together.
In ER positive tumors, cyclin D1 was observed in 46 out of
50 cases (92%), (Fig. 7). While only 7 out of 20 ER negative
tumors (35%) showed positive cyclin D1 expression. The
difference in cyclin D1 expression according to ER statuswas statistically signiﬁcant (p value <0.001). Similarly the dif-
ference in the marker expression regarding PR status was
statistically signiﬁcant (p value <0.001), where 44 of the 46
PR positive tumors (95.6%) showed positive reaction to cyclin
D1, and only 9 of the 24 PR negative tumors (37.5%) were
positive for cyclin D1. There was no signiﬁcant relation be-
tween cyclin D1 expression and tumor size or lymph node sta-
tus (p value = 0.12 and 0.07, respectively), (Table 2).
Discussion
FNA has been used mainly for diagnostic purposes in patients
with breast carcinoma. Accurate assessment of the biologic
properties of the breast tumor preoperatively may provide
patients with more optimal therapy. The wider acceptance of
preoperative chemotherapy for breast carcinoma patients man-
dates the development of methods to measure biologic markers
to predict tumor response and prognosis [13].
Cyclin D1 used in the current study is one of the most
widely investigated molecules in the breast carcinoma. It might
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planning more effective treatment after surgery [17].
CCND1 ampliﬁcation has been extensively investigated in
breast cancer by Southern blotting, ﬂuorescent in situ hybrid-
ization (FISH), and real-time polymerase chain reaction-based
methods with the prevalence ranging from 9% to 24%. Cyclin
D1 protein overexpression by IHC was reported to be more
prevalent than ampliﬁcation, with the reported frequency
ranging from 28% to 83% [18].
On the other hand, some investigators have reported some
staining difﬁculties regarding immunohistochemical cyclin D1
expression. The presence of cyclin D2 or cyclin D3 was
reported to attribute to non speciﬁc cytoplasmic staining
obtained with anti cyclin D1 antibodies on account of the pres-
ence of shared epitopes. This cross reactivity could interfere as
well with the nuclear staining and would be interpreted as false
positive [19]. Accordingly, Western Blotting (WB) was recom-
mended for cyclin D1 assessment based on the property of the
electrophoretic separation of this cyclin from its two other
counterpart family members, cyclin D2 and D3, according to
molecular weight (36, 34 and 32 kD, respectively) on a poly-
acrylamide gel. Thus WB avoids cross reaction problems that
may be obtained in other techniques as IHC or ELISA due to
the presence of shared epitopes [20].
This variation has been explained by many authors. It
might be linked to the different antibodies, techniques, and
thresholds (cutoff points) used [21]. However other authors
conclude that an unidentiﬁed mechanism is operating in some
tumors to cause increased protein expression. Possible mecha-
nisms include alterations to the gene promoter region or
altered expression of a regulatory transcription factor, such
as c-jun. A longer mRNA half life would result in the produc-
tion of more active protein without the necessity for an in-
creased gene copy number or increased transcription [22].
There were several reports that have studied Cyclin D1
expression using tissue sections. However, to our knowledge,
there were only few reports found in the literature regarding
cyclin D1 assay in FNA samples. In the present study, cyclin
D1 immunocytochemical was expressed in 53/70 (75.7%) of
FNAC cases, our results were in agreement with other studies
where expression of Cyclin D1 was 73.7%, and 77.1%
[13,17].
Considering cyclin D1 expression, the rate of concordance
between FNAC and histologic section in our study was
87.1%, this rate was higher than that observed by other studies
that reported a concordance rate of 75% and 81% [13,17]. The
higher rate observed in our study may be due to difference in
the number of cases included in other studies, or due to the
very few reports that have studied cyclin D1 expression in
cytology to compare our results with their work. However,
our results indicated that cyclin D1 immunocytochemical
expression can be used accurately in ﬁne needle aspirated sam-
ples. Kappa showed a value of 0.65 indicating a good agree-
ment between cytologic and histologic results.
In breast carcinoma cell lines, the expression of cyclin D1
precedes estrogen-induced progression through the G1 phase
of the cell cycle [23]. In FNA samples, cyclin D1 expression
was found to be increased signiﬁcantly in ER-positive or PR-
positive breast tumors. If cyclin D1 expression is linked closely
to ER expression in breast tissues, response to tamoxifen treat-
ment could be predicted by assaying cyclin D1 expression in
FNA samples [13].In the current work, a strong association between cyclin D1
immunocytochemical expression and ER as well as PR positiv-
ity was found (p value <0.001), where 92% of ER positive
tumors, and 95.6% of PR positive tumors showed cyclin D1
expression. Similarly, large number of other studies showed
such strong association [13,17,24–31]. A strong association be-
tween estrogen responsive tumor cells and cyclin D1 overex-
pression could be due to induction of cyclin D1 by estrogen
[10].
The majority of studies concerning breast carcinoma had
found that high levels of cyclin D1 expression both in cytologic
and tissue sections were associated with well-differentiated
tumors, and this expression was decreased markedly when
the grade was increased. This suggests that cyclin D1 expres-
sion in primary breast carcinoma may have a differentiation
signal [13,17,29,32–34]. The present study also demonstrated
such signiﬁcant association, where in tissue sections cyclin
D1 was expressed in 83.1% of grade 2 tumors; this expression
decreased to 36.4% in grade 3 tumors.
In the current study, no relation could be detected between
cyclin D1 immunocytochemical expression and either axillary
lymph node status or tumor size (p value 0.07 and 0.12, respec-
tively). Our ﬁndings were similar to most of the other reports
who failed to ﬁnd such relation [10,13,34]. However, other few
studies have found a different pattern of cyclin D1 immunocy-
tochemical expression according to lymph node status [35].
The present study concludes that cyclin D1 immunocyto-
chemical expression can be assessed accurately using FNAC
specimens, with a high agreement with the results of corre-
sponding tissue sections. A relation between cyclin D1 immu-
nocytochemical expression and ER, PR status, histologic and
cytologic grading was well observed. Assessing Cyclin D1
immunocytochemical expression using FNAC helps to deter-
mine tumor biology, and predict the patients who will beneﬁt
from target therapeutic regimen, especially in patients who will
receive pre-operative chemotherapy.
We recommend future studies assessing the ampliﬁcation of
cyclin D1 in breast carcinoma ﬁne needle material using tools
such as WB, FISH, and others, and compare their results with
that of cyclin D1 immunocytochemical expression on ﬁne nee-
dle aspirates to detect the rate of agreement between them.References
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